Robert E. Conway Acquires 10,000 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Director Robert E. Conway bought 10,000 shares of the business’s stock in a transaction on Tuesday, September 21st. The shares were acquired at an average cost of $9.80 per share, for a total transaction of $98,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

ALPN opened at $10.36 on Friday. Alpine Immune Sciences, Inc. has a one year low of $7.21 and a one year high of $16.37. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.32 and a current ratio of 2.32. The stock’s fifty day moving average is $9.22 and its 200-day moving average is $10.26. The company has a market capitalization of $247.76 million, a PE ratio of -7.10 and a beta of 1.65.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings data on Monday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.17). Alpine Immune Sciences had a negative return on equity of 60.24% and a negative net margin of 190.22%. The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $6.59 million. On average, equities research analysts forecast that Alpine Immune Sciences, Inc. will post -1.31 EPS for the current fiscal year.

Several brokerages have weighed in on ALPN. Zacks Investment Research raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, August 18th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Alpine Immune Sciences in a research note on Thursday, June 24th.

Institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. acquired a new stake in shares of Alpine Immune Sciences during the first quarter worth $1,659,000. Hancock Whitney Corp raised its position in shares of Alpine Immune Sciences by 63.2% during the second quarter. Hancock Whitney Corp now owns 18,721 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 7,249 shares during the period. Geode Capital Management LLC raised its position in shares of Alpine Immune Sciences by 19.3% during the first quarter. Geode Capital Management LLC now owns 92,142 shares of the biotechnology company’s stock worth $976,000 after purchasing an additional 14,915 shares during the period. Acadian Asset Management LLC raised its position in shares of Alpine Immune Sciences by 1,736.6% during the first quarter. Acadian Asset Management LLC now owns 48,541 shares of the biotechnology company’s stock worth $515,000 after purchasing an additional 45,898 shares during the period. Finally, Ensign Peak Advisors Inc raised its position in shares of Alpine Immune Sciences by 51.3% during the first quarter. Ensign Peak Advisors Inc now owns 54,580 shares of the biotechnology company’s stock worth $579,000 after purchasing an additional 18,505 shares during the period. 55.07% of the stock is currently owned by institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies.

Further Reading: Stocks Increasing Dividends

Insider Buying and Selling by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.